Skip to content

Stevanato Group

US · STVN #2012 by market cap Listed 2021
19.44 -0.42 -2.11%
Live - 5344 symbols - heartbeat 450s ago · 2026-10-07 20:03
After-hours 19.44 0.00%
Overnight 19.44 0.00%
Market cap
5.31B
P/B
3.06
EPS
0.57
Reader sentiment Are you bullish or bearish on STVN?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
10.70 fair value ≈ 19.88 29.06
  • Implied fair-value range of 10.70-29.06, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -2.2% below the average-multiple fair value of 19.88.

Valuation each multiple against its own 5-year range

P/B ratio 3.13 Cheap vs history 30th percentile
5-year average 3.61 · #29 of 51 in Medical Instruments & Supplies
P/E ratio 36.20 In line with history 47th percentile
5-year average 34.81 · forward 28.10 · #16 of 27 in Medical Instruments & Supplies
P/S ratio 3.94 Cheap vs history 25th percentile
5-year average 4.54 · forward 3.66 · #36 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Stevanato Group (STVN) 5.31B 35.41 3.06 0.32%
Intuitive Surgical (ISRG) 146.44B 47.54 8.06 0.00%
Becton Dickinson & Co (BDX) 49.07B 54.43 2.01 2.33%
ResMed (RMD) 31.78B 21.67 4.83 1.06%
Medline (MDLN) 31.10B 67.27 2.69 0.00%
Alcon (ALC) 30.45B 48.09 1.41 0.56%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value22.27 Economic moatNarrow UncertaintyMedium

Trading 14.6% below Morningstar's fair value estimate.

Fair value

Stevanato Group SpA earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% discount to our quantitative fair value estimate of $22.27 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-07 20:03:48 · For reference only, not investment advice and not tailored to your situation.